| 摘要 |
Use of a compound of the Formula (I) for the manufacture of medicaments for prophylactic treatment of ischemic injury or myocardial infarct size as a consequence of to myocardial ischemia. Wherein, K is N, N?O or CH; Q is CH2 or O; T is R1-N(R2)-C(O)- or R3O-CH2; X is a straight or branched chain alkylene, cycloalkylene or cycloalkenylene group; Y is NR4, O or S; a=0 or 1; Z is of the Formula (II) and (III); wherein Z1 is N, CR5, (CH)m-CR5 or (CH)m-N, m being 1 or 2; Z2 is N, NR6, O or S, n being 0 or 1; R1, R2, R3, R4, R5 and R6 are independently H, alkyl, aryl or heterocyclyl; Ra and Rb are independently H, OH, alkyl, hydroxyalkyl, alkyl mercaptyl, thioalkyl, alkoxy, alkyoxyalkyl, amino, alkyl amino, carboxyl, acyl, halogen, carbamoyl, alkyl carbamoyl, aryl or heterocyclyl; and; R' and R" are independently hydrogen, alkyl, aralkyl, carbamoyl, alkyl carbamoyl, dialkylcarbamoyl, acyl, alkoxycarbonyl, aralkoxycarbonyl, aryloxycarbonyl, or R' and R" together may form Formula (IV), (V), (VI), (VII) where Rc is hydrogen or alkyl, where Rd and Re are independently hydrogen, alkyl, or together with the carbon atom to which they are attached may form a 1,1-cycloalkyl group; provided that when X is straight chain alkylene and Q is oxygen, then Z represents a heterocyclyl including at least two heteroatoms.
|
